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We read the paper by Sen et al. (1) with great interest; the study was
designed to explore whether the instantaneous wave-free ratio (iFR)
was an adenosine-free alternative to fractional ﬂow reserve (FFR)
for the assessment of coronary stenosis. Hyperemic stenosis resis-
tance (HSR) was used as a reference standard to determine when
iFR and FFR disagreed as to which index was most representative
of the hemodynamic signiﬁcance of the stenosis. It was concluded
that iFR and FFR had equivalent agreement with classiﬁcation
of coronary stenosis severity by HSR, and the administration of
adenosine did not improve diagnostic categorization. However, we
have several concerns regarding the data the study presented.
First, the well-designed study only investigated 51 vessels, which
signiﬁcantly reduces the reliability of the result. We noticed that in
the 4 lesions of 2 groups (iFR[] and FFR(þ); iFR(þ) and
FFR[]), in which there was disagreement, HSR agreed with FFR
in 1 case (50%) and with iFR in the other case (50%) for each
group, respectively (1). Based on these data, how could we trust
that iFR and FFR were equally representative of the hemodynamic
signiﬁcance of the stenosis rather than an element of serendipity? It
was not convincible that “the proportion (7.7%) is consistent with
clinical populations, the ADVISE Registry (6%), and South
Korean Study (6%), suggesting that the study ﬁndings are consis-
tent with other, larger datasets” (1).
Second, we noted that “using the established ischemic cut-off point
of>0.8 mmHg/cm$s for HSR (2),” a 0.75 cutoff point for FFR was
found to have an optimal diagnostic efﬁciency of 0.96 (1). The cutoff
for HSR was certainly key to the study, which was used to determine
the cutoff of iFR and FFR and dominated the disagreement betweenthem. However, the problem is that there is no evidence of the so-
called “established ischemic cut-off point of >0.8 mm Hg/cm$s for
HSR” in the study by Christou et al (2). What is wrong with that?
Could we just explain it as a mistake? Because we did ﬁnd a paper (3)
to validate a cutoff of >0.8 mm Hg/cm$s for HSR, which was also
cited in the study. If so, we have to know if this was the only paper
(3) to date to determine such a cutoff of HSR without reproduc-
ibility. Furthermore, possible inﬂuences of hemodynamic alterations
(heart rate, aortic pressure, contractility) on HSR have not been
investigated (3).
In summary, it was of great signiﬁcance for the study to clarify
whether iFR was an adenosine-free alternative to FFR, especially
when the VERIFY (Veriﬁcation of Instantaneous Wave-Free Ratio
and Fractional Flow Reserve for the Assessment of Coronary Artery
Stenosis Severity in Everyday Practice) study (4) indicated that iFR
correlates weakly with FFR and was not independent of hyperemia.
However, maybe we should not take the urgency, but the large-sized
algorithm, to clarify the issue.Moreover, it might be advisable to ﬁnd
a well-validated, pressure-and-ﬂow index as a reference standard.Guo-Xin Fan, MD
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We are honored that Drs. Fan and Xu noticed some differences
between the CLARIFY (Classiﬁcation Accuracy of Pressure-Only
Ratios Against Indices Using Flow Study) (1) and VERIFY
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944(Veriﬁcation of Instantaneous Wave-Free Ratio and Fractional
Flow Reserve for the Assessment of Coronary Artery Stenosis
Severity in Everyday Practice) (2) trials. This detailed analysis is
sorely needed in our community.
In suggesting that “the VERIFY study indicated that instant
wave-free ratio (iFR) correlates weakly with fractional ﬂow reserve
(FFR) and was not independent of hyperemia,” Fan and Xu should
be aware of 2 key points.
First, there are major differences in the way iFR was calculated
in VERIFY compared with our work (3). Some of these differences
are graphically depicted in Figure 1 of the VERIFY paper (2),
clearly demonstrating that Berry et al. failed to identify “diastole.”
Instead, they actually included a portion of systole in their “diastolic
period.” As readers are aware, resistance during systole is neither
constant nor minimized; such basic methodological errors may
explain why iFR–FFR classiﬁcation match was signiﬁcantly lower
in VERIFY than in any other reported comparative study (Fig. 1).
When the analysis was performed by an independent neutral third
party using the validated iFR algorithm in RESOLVE (4), the
claims of the VERIFY investigators could not be substantiated
(with 80% iFR–FFR agreement rather than the 51% to 60%
reported by Berry et al. [2]). An additional reason for the poor
iFR–FFR match in VERIFY could be due to the variable iFR
cutpoint used within the same study. For example, an iFR cutpoint
of 0.83 was used in the results section of VERIFY, whereas,
confusingly, in the abstract, they report data for an iFR cutpoint of
0.80. In reality, Berry et al. (2) knew the optimal receiver-operating
characteristic derived cutpoint for VERIFY-iFR in their dataset
was neither. Playing with numbers in this manner can only depress
any possible link between iFR and FFR. We encourage the read-
ership to check whether the early FFR work identiﬁed an optimal
cutpoint and then in the same dataset deliberately used a subop-
timal one.Figure 1 Summary of iFR–FFR Comparison Data Contributing to the RESOLVE
Green circles denote studies using the wave-intensity validated imperial college algorithm
FFR ¼ fractional ﬂow reserve; FORECAST ¼ TCT-230 Instantaneous Wave-Free Ratio and
Reserve; KCL-AMC¼ King’s College London–Academic Medical Center (Amsterdam); VERIF
Assessment of Coronary Artery Stenosis Severity in Everyday Practice.Second, demonstrating that iFR was independent of hyperemia
was never an objective or a claim of our work, but instead, we
simply aimed to achieve stenosis classiﬁcation similar to that
obtained with FFR but without (or independent of) the need of
adenosine administration. However, it is important to note that
CLARIFY (1) demonstrated that adding adenosine infusion to the
iFR calculation did not improve diagnostic accuracy, rendering the
key ﬁnding of VERIFY clinically irrelevant.
Regarding the validation of hyperemic stenosis resistance (HSR),
we believe that the publications by Meuwissen et al. (5) provide
sufﬁcient evidence for its use as a valid reference standard in our
study. HSR has the advantage of having a better discriminant value
than FFR because it really does measure ﬂow, which is the crucial
feature for the thirsting myocardium. Among studies of this kind,
which used ﬂow and pressure, CLARIFY is the second-largest ever
conducted, and the ﬁrst to publish. The vintage physiological studies
of FFR were smaller, and as underlined by Fan and Xu, reported
diagnostic accuracies that were later overturned by larger studies from
independent investigators (6) (as is the also the case for VERIFY).
Although CLARIFY demonstrated iFR to be noninferior to
FFR, we are honored to report that the world’s largest comparison
of iFR and FFR against HSR has been performed by a team
including the FFR pioneers, Pijls and Gould (7). This independent
analysis of 120 stenoses suggests iFR may be superior to FFR. Is
this more serendipity?*Sayan Sen, MBBS
Javier Escaned, MD, PhD
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. Other colors represent investigator-derived instantaneous wave-free ratio (iFR).
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Forest Plot for the Effect of Dabigatran Versus Control on
Incident MI
CI ¼ conﬁdence interval; MI ¼ myocardial infarction; RE-COVER ¼ Dabigatran
versus Warfarin in the Treatment of Acute Venous Thromboembolism; RE-DEEM ¼
RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute
Coronary Syndromes Post Index Event With Additional Risk Factors for Cardio-
vascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre,
Prospective, Placebo Controlled, Cohort Dose Escalation Study; RE-LY ¼
Randomized Evaluation of Long-Term Anticoagulation Therapy; RE-MEDY ¼ A
Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled
Study to Evaluate the Efﬁcacy and Safety of Oral Dabigatran Etexilate (150 mg bid)
Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous
Thromboembolism; RE-SONATE ¼ Twice-daily Oral Direct Thrombin Inhibitor
Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic
Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein
Thrombosis or Pulmonary Embolism.Dabigatran’s ‘Real-World’ Data
About Risk of Myocardial
Infarction and Gastrointestinal
Bleeding Contradicts With
Randomized Trials
We read with great interest the article by Larsen et al. (1) examining
the safety of dabigatran, especially with regard to myocardial
infarction (MI) and gastrointestinal bleeding using Danish national
databases. They report a remarkable, highly signiﬁcant 60% to 70%
risk reduction in MIs with dabigatran as compared with warfarin
(p < 0.0001). Similarly, they report a 40% reduction in incident
gastrointestinal bleeding with 110 mg dabigatran twice daily
compared with warfarin, which was again statistically signiﬁcant.
While examination of observational administrative datasets may
sometimes be helpful to answer certain questions, the gold standard
for determining drug safety and efﬁcacy is careful analysis of allavailable randomized controlled clinical trials. With regard to MI,
several randomized trials have reported data with dabigatran. All of
these studies (except the RE-SONATE [Twice-daily Oral Direct
Thrombin Inhibitor Dabigatran Etexilate in the Long-term
Prevention of Recurrent Symptomatic Proximal Venous Throm-
boembolism in Patients With Symptomatic Deep-vein Thrombosis
or Pulmonary Embolism] trial with only single events in each arm)
showed a numerical excess in MIs with dabigatran (2–6).
Combined analysis of all these trials shows a 48% increase in MIs
with dabigatran as compared to controls (p ¼ 0.005) (Fig. 1).
Removal of any single study, including the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy) trial (3) that
generated the hypothesis that dabigatran increases risk of MI, does
not change the statistically signiﬁcant excess in MIs. On the other
hand, regarding the gastrointestinal bleeding risk, the RE-LY trial
reported this event in 10% of patients receiving dabigatran 110 mg
twice daily and in 7.5% of patients receiving warfarin (p < 0.00001
for dabigatran vs. warfarin) (2). In this trial the excess in gastro-
intestinal bleeding events was even more pronounced for dabigatran
150 mg twice daily compared with warfarin. The RE-COVER
(Dabigatran versus Warfarin in the Treatment of Acute Venous
Thromboembolism) trial also showed an excess in gastrointestinal
bleeding with dabigatran as compared with warfarin (4.2% vs.
2.8%) (5). Therefore, the results of both the Larsen et al. (1) current
observational study and the randomized controlled clinical trials
show signiﬁcant differences in MI and gastrointestinal bleeding
rates with dabigatran versus warfarin, but in completely opposite
directions. We think that the imperfect nature of observational
studies mostly stemming from residual confounding despite
propensity matching may explain the discrepancy between the
current observational study and previous randomized trials. Can the
authors provide their perspective on the risk of residual con-
founding in their analysis?
